156 related articles for article (PubMed ID: 23419151)
1. Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma.
Reijmers RM; Spaargaren M; Pals ST
FEBS J; 2013 May; 280(10):2180-93. PubMed ID: 23419151
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
3. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.
Mahtouk K; Cremer FW; Rème T; Jourdan M; Baudard M; Moreaux J; Requirand G; Fiol G; De Vos J; Moos M; Quittet P; Goldschmidt H; Rossi JF; Hose D; Klein B
Oncogene; 2006 Nov; 25(54):7180-91. PubMed ID: 16732320
[TBL] [Abstract][Full Text] [Related]
4. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
[TBL] [Abstract][Full Text] [Related]
5. Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.
Lanzi C; Zaffaroni N; Cassinelli G
Curr Med Chem; 2017; 24(26):2860-2886. PubMed ID: 28215163
[TBL] [Abstract][Full Text] [Related]
6. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.
Reijmers RM; Groen RW; Rozemuller H; Kuil A; de Haan-Kramer A; Csikós T; Martens AC; Spaargaren M; Pals ST
Blood; 2010 Jan; 115(3):601-4. PubMed ID: 19965677
[TBL] [Abstract][Full Text] [Related]
7. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2020 Aug; 178():114084. PubMed ID: 32526230
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans.
van der Voort R; Keehnen RM; Beuling EA; Spaargaren M; Pals ST
J Exp Med; 2000 Oct; 192(8):1115-24. PubMed ID: 11034601
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation.
Fisher MC; Li Y; Seghatoleslami MR; Dealy CN; Kosher RA
Matrix Biol; 2006 Jan; 25(1):27-39. PubMed ID: 16226436
[TBL] [Abstract][Full Text] [Related]
11. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential.
Yang H; Wang L
Adv Cancer Res; 2023; 157():251-291. PubMed ID: 36725112
[TBL] [Abstract][Full Text] [Related]
13. Syndecan-1 in B lymphoid malignancies.
Sanderson RD; Børset M
Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
[TBL] [Abstract][Full Text] [Related]
14. Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment.
De Pasquale V; Pavone LM
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32916872
[TBL] [Abstract][Full Text] [Related]
15. Localisation of specific heparan sulfate proteoglycans during the proliferative phase of brain development.
Ford-Perriss M; Turner K; Guimond S; Apedaile A; Haubeck HD; Turnbull J; Murphy M
Dev Dyn; 2003 Jun; 227(2):170-84. PubMed ID: 12761845
[TBL] [Abstract][Full Text] [Related]
16. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2.
Clayton A; Thomas J; Thomas GJ; Davies M; Steadman R
Kidney Int; 2001 Jun; 59(6):2084-94. PubMed ID: 11380810
[TBL] [Abstract][Full Text] [Related]
17. Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.
Stewart MD; Ramani VC; Sanderson RD
J Biol Chem; 2015 Jan; 290(2):941-9. PubMed ID: 25404732
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Regulation of the Biosynthesis & Enzymatic Modification of Heparan Sulfate Proteoglycans: Implications for Tumorigenesis and Cancer Biomarkers.
Hull EE; Montgomery MR; Leyva KJ
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28672878
[TBL] [Abstract][Full Text] [Related]
20. Regulation of ureteric bud branching morphogenesis by sulfated proteoglycans in the developing kidney.
Steer DL; Shah MM; Bush KT; Stuart RO; Sampogna RV; Meyer TN; Schwesinger C; Bai X; Esko JD; Nigam SK
Dev Biol; 2004 Aug; 272(2):310-27. PubMed ID: 15282150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
